|
1）Uhlig K, Berns JS, Kestenbaum B, et al. KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis. 2010; 55: 773-992
|
|
|
|
2）Stenvinkel P, Heimburger O, Paultre F, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999; 55: 1899-911
|
|
|
|
|
|
3）慢性腎臓病に伴う骨・ミネラル代謝異常の診療ガイドライン. 透析会誌. 2012; 45(4): 301-56
|
|
|
|
|
|
4）Drechsler C, Verduijn M, Pilz S, et al; NECOSAD Study Group. Bone alkaline phosphatase and mortality in dialysis patients. Clin J Am Soc Nephrol. 2011; 6: 1752-9
|
|
|
|
|
|
5）Yamashita T, Okano K, Tsuruta Y, et al. Serum osteocalcin levels are useful as a predictor of cardiovascular events in maintenance hemodialysis patients. Int Urol Nephrol. 2012 (in press)
|
|
|
|
|
|
6）Fahrleitner-Pammer A, Herberth J, Browning SR, et al. Bone markers predict cardiovascular events in chronic kidney disease. J Bone Miner Res. 2008; 23: 1850-8
|
|
|
|
|
|
7）Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008; 359: 584-92
|
|
|
|
|
|
8）Mirza MA, Larsson A, Melhus H, et al. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis. 2009; 207: 546-51
|
|
|
|
|
|
9）Olauson H, Qureshi AR, Miyamoto T, et al. Relation between serum fibroblast growth factor-23 level and mortality in incident dialysis patients: are gender and cardiovascular disease confounding the relationship? Nephrol Dial Transplant. 2010; 25: 3033-8
|
|
|
|
|
|
10）Morena M, Terrier N, Jaussent I, et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol. 2006; 17: 262-70
|
|
|
|
|
|
11）Ozkok A, Caliskan Y, Sakaci T, et al. Osteoprotegerin/RANKL axis and progression of coronary artery calcification in hemodialysis patients. Clin J Am Soc Nephrol. 2012; 7: 965-73
|
|
|
|
|
|
12）Koo HM, Do HM, Kim EJ, et al. Elevated osteoprotegerin is associated with inflammation, malnutrition and new onset cardiovascular events in peritoneal dialysis patients. Atherosclerosis. 2011; 219: 925-30
|
|
|
|
|
|
13）Talib A, Nakagawa N, Saito E, et al. The balance of fetuin-A and osteoprotegerin is independently associated with diastolic dysfunction in hemodialysis patients. Hypertens Res. 2012; 35: 426-33
|
|
|
|
|
14）Pertosa G, Simone S, Ciccone M, et al. Serum fetuin a in hemodialysis: a link between derangement of calcium-phosphorus homeostasis and progression of atherosclerosis? Am J Kidney Dis. 2009; 53: 467-74
|
|
|
|
|
|
15）Cranenburg EC, Brandenburg VM, Vermeer C, et al. Uncarboxylated matrix Gla protein (ucMGP) is associated with coronary artery calcification in haemodialysis patients. Thromb Haemost. 2009; 101: 359-66
|
|
|
|
|
|
16）Honda H, Qureshi AR, Heimburger O, et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin A as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis. 2006; 47: 139-48
|
|
|
|
|
|
17）血液透析患者における心血管合併症の評価と治療に関するガイドライン. 透析会誌. 2011; 44 (5): 337-425
|
|
|
|
|
|
18）Wang AY, Lam CW, Chan IH, et al. Prognostic value of plasma myeloperoxidase in ESRD patients. Am J Kidney Dis. 2010; 56: 937-46
|
|
|
|
|
|
19）Honda H, Ueda M, Kojima S, et al. Assessment of myeloperoxidase and oxidative alpha1-antitrypsin in patients on hemodialysis. Clin J Am Soc Nephrol. 2009; 4: 142-51
|
|
|
|
|
|
20）Meerwaldt R, Zeebregts CJ, Navis G, et al. Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis. Am J Kidney Dis. 2009; 53: 138-50
|
|
|
|
|
|
21）Nishizawa Y, Koyama H, Inaba M. AGEs and cardiovascular diseases in patients with end-stage renal diseases. J Ren Nutr. 2012; 22: 128-33
|
|
|
|
|
|
22）Furuya R, Kumagai H, Miyata T, et al. High plasma pentosidine level is accompanied with cardiovascular events in hemodialysis patients. Clin Exp Nephrol. 2012; 16: 421-6
|
|
|
|
|
|
23）Kim JK, Park S, Lee MJ, et al. Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis. Atherosclerosis. 2012; 220(1): 208-14
|
|
|
|
|
|
24）Girndt M, Kaul H, Sester U, et al. Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events. Kidney Int. 2002; 62: 949-55
|
|
|
|
|
|
25）Honda H, Ueda M, Kojima S, et al. Oxidized high-density lipoprotein as a risk factor for cardiovascular events in prevalent hemodialysis patients. Atherosclerosis. 2012; 220: 493-501
|
|
|
|
|
|
26）Hayashi M, Shibata R, Takahashi H, et al. Association of adiponectin with carotid arteriosclerosis in predialysis chronic kidney disease. Am J Nephrol. 2011; 34: 249-55
|
|
|
|
|
|
27）Amira OC, Naicker S, Manga P, et al. Adiponectin and atherosclerosis risk factors in African hemodialysis patients: a population at low risk for atherosclerotic cardiovascular disease. Hemodial Int. 2012; 16: 59-68
|
|
|
|
|
|
28）Papagianni A, Dovas S, Bantis C, et al. Carotid atherosclerosis and endothelial cell adhesion molecules as predictors of long-term outcome in chronic hemodialysis patients. Am J Nephrol. 2008; 28: 265-74
|
|
|
|
|
|
29）Boehme M, Kaehne F, Kuehne A, et, al. Pentraxin 3 is elevated in haemodialysis patients and is associated with cardiovascular disease. Nephrol Dial Transplant. 2007; 22: 2224-9
|
|
|
|
|
|
30）Xu Y, Ding X, Zou J, et al. Plasma pentraxin 3 is associated with cardiovascular disease in hemodialysis patients. Ren Fail. 2011; 33(10): 998-1004
|
|
|
|
|
|
31）Yilmaz MI, Carrero JJ, Ortiz A, et al. Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2009; 4: 1716-23
|
|
|
|
|
|
32）Mallamaci F, Benedetto FA, Tripepi G, et al. Vascular endothelial growth factor, left ventricular dysfunction and mortality in hemodialysis patients. J Hypertens. 2008; 26: 1875-82
|
|
|
|
|
|
33）Guo Q, Carrero JJ, Yu X, et al. Associations of VEGF and its receptors sVEGFR-1 and -2 with cardiovascular disease and survival in prevalent haemodialysis patients. Nephrol Dial Transplant. 2009; 24: 3468-73
|
|
|
|
|